[ET Net News Agency, 24 December 2024] Morgan Stanley lowered the target price for Sh
Pharma (02607) to HKD17 from HKD18.4 and maintained the "overweight" rating.
The research house said following 3Q24, it cuts 2024-30e earnings by 3-9% on lower
sales. (rc)